Santen is launching low-dose atropine (Ryjunea) in Germany following its approval from the European Commission in June for myopia management. Additional launches across Europe are expected to follow soon; expansion is also planned for the Middle East and Africa.

The SYD-101 formulation of atropine is licensed by Santen SA from Sydnexis Inc. It is indicated for slowing the progression of myopia in children aged 3-14 years with –0.50 D to –6.00 D of error and a progression rate of 0.50 D per year.

Additionally, Santen has obtained manufacturing and marketing approval in Japan for mini ophthalmic solution 0.025% (Ryjusea), which utilizes the same active molecule as Ryjunea, atropine sulfate hydrate. It is the first myopia management ophthalmic solution to be approved for production and marketing in Japan. It  will be sold as a drug not listed in the National Health Insurance Drug Price Standard and is not covered by insurance. Ryjusea launched in Japan in April 2025.